Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, Ahmed N, Schachter L, Bharucha K, Dholaria BR, Schuster SJ, Perales MA, Bishop MR, Porter DL.
Riedell PA, et al. Among authors: bharucha k.
Transplant Cell Ther. 2022 Oct;28(10):669-676. doi: 10.1016/j.jtct.2022.07.011. Epub 2022 Jul 16.
Transplant Cell Ther. 2022.
PMID: 35850429
Free PMC article.